Author

E. P. Erkan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:scRNA-seq· 2 Assay:spatial transcriptomics· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Virtanen· 4 shared S. Hautaniemi· 4 shared J. Hynninen· 3 shared J. Oikkonen· 3 shared M. M. Falco· 3 shared Y. Li· 3 shared A. Farkkila· 2 shared A. Szabo· 2 shared

Activity by Year

2022-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Virtanen

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Multi-Omics Analysis Reveals the Attenuation of the Interferon Pathway as a Driver of Chemo-Refractory Ovarian Cancer

D. Afenteva, R. Yu, A. Rajavuori, M. Salvadores, I.-M. Launonen, K. Lavikka, K. Zhang, G. Marchi, S. Jamalzadeh, V.-M. Isoviita, Y. Li, G. Micoli, E. P. Erkan, M. M. Falco, D. Ungureanu, , S. Hautaniemi

The paper identifies reduced IFN-I pathway activity as a driver of chemo-refractory ovarian cancer using multi-omics analysis in a clinical trial cohort.

bioRxiv · Mar 28, 2024Cancer Biology

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer

I.-M. P. Launonen, E. P. Erkan, I. Niemiec, A. Junquera, M. Hincapie-Otero, D. Afenteva, Z. Liang, M. Salko, A. Szabo, F. Perez-Villatoro, M. M. Falco, Y. Li, G. Micoli, A. Nagaraj, U.-M. Haltia, , A. Farkkila

This study shows chemotherapy causes myeloid-driven spatial T-cell exhaustion in ovarian cancer by altering immune cell states and interactions, suggesting new immunotherapy approaches.

bioRxiv · Mar 19, 2024 · PreprintCancer Biology

Patient-derived functional immuno-oncology platform identifies responders to ATR inhibitor and immunotherapy combinations in ovarian cancer

A. S. Nagaraj, M. Salko, A. Sirsikar, E. P. Erkan, E. A. Pietilä, I. Niemiec, J. Bao, G. Marchi, A. Szabo, K. Nowlan, S. Pikkusaari, A. Kanerva, J. Tapper, R. Koivisto-Korander, L. Kauppi, , A. Färkkilä

bioRxiv · Feb 15, 2024 · PreprintCancer Biology

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

W. Senkowski, L. Gall-Mas, M. M. Falco, Y. Li, K. Lavikka, M. C. Kriegbaum, J. Oikkonen, D. Bulanova, E. J. Pietras, K. Vossgröne, Y.-J. Chen, E. P. Erkan, M. K. Gronning Hog, I. M. Larsen, T. Lamminen, , K. Wennerberg

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

bioRxiv · Apr 21, 2022Cancer Biology